BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 2784349)

  • 1. Combination cytokine immunotherapy with tumor necrosis factor alpha, interleukin 2, and alpha-interferon and its synergistic antitumor effects in mice.
    McIntosh JK; Mulé JJ; Krosnick JA; Rosenberg SA
    Cancer Res; 1989 Mar; 49(6):1408-14. PubMed ID: 2784349
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha.
    McIntosh JK; Mulé JJ; Merino MJ; Rosenberg SA
    Cancer Res; 1988 Jul; 48(14):4011-7. PubMed ID: 3260130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synergistic antitumor effects of combination immunotherapy with recombinant interleukin-2 and a recombinant hybrid alpha-interferon in the treatment of established murine hepatic metastases.
    Cameron RB; McIntosh JK; Rosenberg SA
    Cancer Res; 1988 Oct; 48(20):5810-7. PubMed ID: 3262413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo.
    Krosnick JA; Mulé JJ; McIntosh JK; Rosenberg SA
    Cancer Res; 1989 Jul; 49(14):3729-33. PubMed ID: 2736513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Studies on the anti-tumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo.
    Asher A; Mulé JJ; Reichert CM; Shiloni E; Rosenberg SA
    J Immunol; 1987 Feb; 138(3):963-74. PubMed ID: 3805720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo induction of IL-6 by administration of exogenous cytokines and detection of de novo serum levels of IL-6 in tumor-bearing mice.
    McIntosh JK; Jablons DM; Mulé JJ; Nordan RP; Rudikoff S; Lotze MT; Rosenberg SA
    J Immunol; 1989 Jul; 143(1):162-7. PubMed ID: 2499626
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of effects of recombinant human tumor necrosis factor on autochthonous tumor and transplanted normal tissue in mice.
    McIntosh JK; Mulé JJ; Travis WD; Rosenberg SA
    Cancer Res; 1990 Apr; 50(8):2463-9. PubMed ID: 2317830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor activity of recombinant human tumor necrosis factor in combination with hyperthermia, chemotherapy, or immunotherapy.
    Haranaka K; Sakurai A; Satomi N
    J Biol Response Mod; 1987 Aug; 6(4):379-91. PubMed ID: 3625230
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models.
    Winkelhake JL; Stampfl S; Zimmerman RJ
    Cancer Res; 1987 Aug; 47(15):3948-53. PubMed ID: 3496953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors.
    Iigo M; Sakurai M; Tamura T; Saijo N; Hoshi A
    Cancer Res; 1988 Jan; 48(2):260-4. PubMed ID: 2446744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapy of disseminated NK-resistant tumor by the synergistic effects of recombinant interleukin-2 and tumor necrosis factor.
    Agah R; Malloy B; Sherrod A; Bean P; Girgis E; Mazumder A
    J Biol Response Mod; 1988 Apr; 7(2):140-51. PubMed ID: 3258905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of recombinant interleukin-1 alpha, recombinant interleukin-2, recombinant interferon-beta, and recombinant tumor necrosis factor on subcutaneously implanted adenocarcinoma 755 and Lewis lung carcinoma.
    Iigo M; Nishikata K; Hoshi A
    J Biol Response Mod; 1990 Aug; 9(4):426-30. PubMed ID: 2395006
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
    Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
    Lafreniere R; Rosenberg SA
    J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Manipulation of oxygen radical-scavenging capacity in mice alters host sensitivity to tumor necrosis factor toxicity but does not interfere with its antitumor efficacy.
    Hauser GJ; McIntosh JK; Travis WD; Rosenberg SA
    Cancer Res; 1990 Jun; 50(12):3503-8. PubMed ID: 2340500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
    Pak AS; Ip G; Wright MA; Young MR
    Cancer Res; 1995 Feb; 55(4):885-90. PubMed ID: 7850804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological and antitumor effects of recombinant human macrophage colony-stimulating factor in mice.
    Bock SN; Cameron RB; Kragel P; Mulé JJ; Rosenberg SA
    Cancer Res; 1991 May; 51(10):2649-54. PubMed ID: 2021943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo administration of interferon alpha and interleukin 2 induces proliferation of lymphoid cells in the organs of mice.
    Puri RK; Travis WD; Rosenberg SA
    Cancer Res; 1990 Sep; 50(17):5543-50. PubMed ID: 2386960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.